前瞻性二期Synergy试验成功结果支持Signatera™ MRD导向疗法在头颈癌中的应用

美股速递
Feb 24

Natera公司宣布,其前瞻性二期Synergy试验取得积极数据,验证了Signatera™微小残留病灶(MRD)检测技术在头颈癌治疗指导中的临床价值。该研究结果标志着个体化精准医疗在实体瘤领域的重要突破,为通过MRD动态监测优化治疗策略提供了新依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10